monoclonal antibodies

Summary

Summary: Antibodies produced by clones of cells such as those isolated after hybridization of activated B LYMPHOCYTES with neoplastic cells. These hybrids are often referred to as HYBRIDOMAS.

Top Publications

  1. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
  2. ncbi Trastuzumab--mechanism of action and use in clinical practice
    Clifford A Hudis
    Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 357:39-51. 2007
  3. ncbi Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
    J Keane
    Pulmonary Center, Department of Medicine, Boston University School of Medicine, MA 02118, USA
    N Engl J Med 345:1098-104. 2001
  4. pmc Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals
    Davide Corti
    Institute for Research in Biomedicine, Bellinzona, Switzerland
    PLoS ONE 5:e8805. 2010
  5. pmc Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
    A Trkola
    Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016, USA
    J Virol 70:1100-8. 1996
  6. ncbi ERBB receptors and cancer: the complexity of targeted inhibitors
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Nat Rev Cancer 5:341-54. 2005
  7. doi Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    Carsten Bokemeyer
    University Hospital, Hamburg Eppendorf, Hamburg Eppendorf, Germany
    J Clin Oncol 27:663-71. 2009
  8. ncbi The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo
    Ferdinand C Breedveld
    Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, C4 R Postbox 9600, Leiden 2300 RC, The Netherlands
    Arthritis Rheum 54:26-37. 2006
  9. ncbi Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Herbert Hurwitz
    Duke University, Durham, NC, USA
    N Engl J Med 350:2335-42. 2004
  10. ncbi CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006

Detail Information

Publications363 found, 100 shown here

  1. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
    ..By expressing immunoglobulin genes from individual cells, we identified three monoclonal antibodies, including a pair of somatic variants that neutralized over 90% of circulating HIV-1 isolates...
  2. ncbi Trastuzumab--mechanism of action and use in clinical practice
    Clifford A Hudis
    Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 357:39-51. 2007
  3. ncbi Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
    J Keane
    Pulmonary Center, Department of Medicine, Boston University School of Medicine, MA 02118, USA
    N Engl J Med 345:1098-104. 2001
    ..There is no direct evidence of a protective role of TNF-alpha in patients with tuberculosis...
  4. pmc Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals
    Davide Corti
    Institute for Research in Biomedicine, Bellinzona, Switzerland
    PLoS ONE 5:e8805. 2010
    The isolation of human monoclonal antibodies (mAbs) that neutralize a broad spectrum of primary HIV-1 isolates and the characterization of the human neutralizing antibody B cell response to HIV-1 infection are important goals that are ..
  5. pmc Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
    A Trkola
    Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016, USA
    J Virol 70:1100-8. 1996
    ..consistent with this, antibodies able to block 2G12 binding to recombinant gp120 were not detected in significant quantities in 16 HIV-positive human serum samples...
  6. ncbi ERBB receptors and cancer: the complexity of targeted inhibitors
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Nat Rev Cancer 5:341-54. 2005
    ..We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response...
  7. doi Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    Carsten Bokemeyer
    University Hospital, Hamburg Eppendorf, Hamburg Eppendorf, Germany
    J Clin Oncol 27:663-71. 2009
    ..The influence of KRAS mutation status was investigated...
  8. ncbi The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo
    Ferdinand C Breedveld
    Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, C4 R Postbox 9600, Leiden 2300 RC, The Netherlands
    Arthritis Rheum 54:26-37. 2006
    ..To compare the efficacy and safety of adalimumab plus methotrexate (MTX) versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive rheumatoid arthritis (RA) who had not previously received MTX treatment...
  9. ncbi Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Herbert Hurwitz
    Duke University, Durham, NC, USA
    N Engl J Med 350:2335-42. 2004
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy...
  10. ncbi CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006
    ..We aimed to compare CHOP-like chemotherapy and rituximab with CHOP-like chemotherapy alone in these patients...
  11. pmc Monoclonal antibodies: versatile platforms for cancer immunotherapy
    Louis M Weiner
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Nat Rev Immunol 10:317-27. 2010
    ..These immunomodulatory properties can form the basis for new cancer treatment strategies...
  12. ncbi Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    D J Slamon
    Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
    N Engl J Med 344:783-92. 2001
    ..The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor...
  13. ncbi Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
    Matthew C Franklin
    Department of Protein Engineering, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94114 USA
    Cancer Cell 5:317-28. 2004
    ..We have also shown that conserved residues previously shown to be necessary for EGF receptor homodimerization may be dispensible for ErbB2-ErbB3 heterodimerization...
  14. pmc Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells
    Mark Throsby
    Crucell Holland BV, Leiden, The Netherlands
    PLoS ONE 3:e3942. 2008
    ..Furthermore, there are 16 different HA subtypes and no certainty the next pandemic will be caused by an H5 subtype, thus it is important to develop prophylactic and therapeutic interventions that provide heterosubtypic protection...
  15. doi K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
    ..The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value...
  16. ncbi Antibody domain exchange is an immunological solution to carbohydrate cluster recognition
    Daniel A Calarese
    Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 300:2065-71. 2003
    ..The unique interdigitation of Fab domains within an antibody uncovers a previously unappreciated mechanism for high-affinity recognition of carbohydrate or other repeating epitopes on cell or microbial surfaces...
  17. ncbi Ranibizumab for neovascular age-related macular degeneration
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    N Engl J Med 355:1419-31. 2006
    ..Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration...
  18. pmc The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120
    Rogier W Sanders
    Dept of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Virol 76:7293-305. 2002
    ....
  19. doi Platinum-based chemotherapy plus cetuximab in head and neck cancer
    Jan B Vermorken
    Antwerp University Hospital, Department of Medical Oncology, Edegem, Belgium
    N Engl J Med 359:1116-27. 2008
    ..We investigated the efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck...
  20. doi Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    Eric Van Cutsem
    University Hospital Gasthuisberg, Digestive Oncology Unit, Herestraat 49, 3000 Leuven, Belgium
    N Engl J Med 360:1408-17. 2009
    ....
  21. ncbi Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    Guillaume Cartron
    Service d Oncologie Médicale et Maladies du Sang et Laboratoire d Immunologie, Centre Hospitalier Régional et Universitaire de Tours, 37044 Tours Cedex, France
    Blood 99:754-8. 2002
    ..This finding will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas...
  22. ncbi Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
    Hyun Soo Cho
    Department of Biophysics and Biophysical Chemistry, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, Maryland 21205, USA
    Nature 421:756-60. 2003
    ..Herceptin binds to the juxtamembrane region of HER2, identifying this site as a target for anticancer therapies...
  23. pmc Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)
    Michelle A Lowes
    Laboratory for Investigative Dermatology and Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 102:19057-62. 2005
    ....
  24. pmc Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning
    Thomas Tiller
    Max Planck Institute for Infection Biology, D 10117 Berlin, Germany
    J Immunol Methods 329:112-24. 2008
    ..In summary, our method to clone and express human monoclonal antibodies is unbiased, highly efficient, requires only small cell numbers and the recombinant antibodies allow ..
  25. doi Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
    Robert Pirker
    Medical University of Vienna, Vienna, Austria
    Lancet 373:1525-31. 2009
    ..We therefore compared chemotherapy plus cetuximab with chemotherapy alone in patients with advanced EGFR-positive non-small-cell lung cancer...
  26. doi Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
    Jolien Tol
    Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    N Engl J Med 360:563-72. 2009
    ..We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer...
  27. pmc The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120
    Christopher N Scanlan
    The Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, United Kingdom
    J Virol 76:7306-21. 2002
    ....
  28. pmc Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
    P W Parren
    Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 75:8340-7. 2001
    ..The significance of such substerilizing neutralizing antibody titers in the context of a potent cellular immune response is an important area for further study...
  29. doi Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
    Helena Linardou
    1st Department of Medical Oncology, Metropolitan Hospital, Athens, Greece
    Lancet Oncol 9:962-72. 2008
    ..EGFR) tyrosine-kinase inhibition in patients with non-small-cell lung cancer (NSCLC), and to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer (mCRC)...
  30. ncbi CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor
    Rebecca S McHugh
    Cellular Immunology Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 16:311-23. 2002
    ..Importantly, antibodies to GITR abrogated suppression, demonstrating a functional role for this receptor in regulating the CD4(+)CD25(+) T cell subset...
  31. ncbi Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
    James J Vredenburgh
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:4722-9. 2007
    ..We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan...
  32. ncbi Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte
    P Feugier
    Hematology Department, Centre Hospitalier Universitaire de Brabois, 54500 Vandoeuvre les Nancy, France
    J Clin Oncol 23:4117-26. 2005
    ....
  33. ncbi Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    Barton F Haynes
    Duke University School of Medicine, Durham, NC 27710, USA
    Science 308:1906-8. 2005
    ..Although rare human monoclonal antibodies (mAbs) exist that broadly neutralize HIV-1, HIV-1 envelope immunogens do not induce these antibody ..
  34. pmc New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets
    Robert H E Friesen
    Crucell Holland BV, Leiden, The Netherlands
    PLoS ONE 5:e9106. 2010
    ..A recently discovered class of human monoclonal antibodies with the ability to neutralize a broad spectrum of influenza viruses (including H1, H2, H5, H6 and H9 ..
  35. pmc Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    James M Binley
    IMM2, Department of Immunology, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 78:13232-52. 2004
    Broadly neutralizing monoclonal antibodies (MAbs) are potentially important tools in human immunodeficiency virus type 1 (HIV-1) vaccine design...
  36. pmc Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L
    Ann J Hessell
    Department of Immunology and Microbial Science and the International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, CA 92037, USA
    J Virol 84:1302-13. 2010
    ..Three broadly neutralizing monoclonal antibodies (bnMAbs), 2F5, 4E10, and Z13e1, are directed against linear epitopes mapped to the MPER, making this ..
  37. ncbi Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group
    Michael A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Rockledge, PA, USA
    J Clin Oncol 21:283-90. 2003
    ..To evaluate the feasibility, toxicity, and efficacy of single-agent monoclonal antibody therapy targeting the human epidermal growth factor receptor 2 (HER2)/neu receptor in ovarian and primary peritoneal carcinoma...
  38. ncbi Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  39. ncbi A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    Chris H Polman
    Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    N Engl J Med 354:899-910. 2006
    ..Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis...
  40. ncbi Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis
    A Moretta
    Dipartimento di Medicina Sperimentale, Universita degli Studi di Genova, Italy
    Annu Rev Immunol 19:197-223. 2001
    ..b>Monoclonal antibodies (mAbs) to NCR block to differing extents the NK-mediated lysis of various tumors...
  41. ncbi Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
    Rita Nahta
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030 4009, USA
    Nat Clin Pract Oncol 3:269-80. 2006
    ..Novel therapies targeted against these aberrant molecular pathways offer hope that the effectiveness and duration of response to trastuzumab can be greatly improved...
  42. pmc Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance
    Laura Bonifaz
    Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY 10021, USA
    J Exp Med 196:1627-38. 2002
    ..Therefore, DEC-205 provides an efficient receptor-based mechanism for DCs to process proteins for MHC class I presentation in vivo, leading to tolerance in the steady state and immunity after DC maturation...
  43. ncbi Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    David B Agus
    Cedars Sinai Prostate Cancer Center, Los Angeles, California 90048, USA
    Cancer Cell 2:127-37. 2002
    ..We demonstrate that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment...
  44. ncbi Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
    Johanna C Bendell
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 97:2972-7. 2003
    ..Women with HER-2 overexpressing metastatic breast carcinoma benefit from trastuzumab-based therapy, but trastuzumab does not cross the blood-brain barrier. The authors characterized central nervous system (CNS) disease in these women...
  45. pmc Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    Giao Q Phan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:8372-7. 2003
    ..This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy...
  46. ncbi Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
    Maurizio Scaltriti
    Medical Oncology Program, Medical Oncology Department, Vall d Hebron University Hospital and Research Institute, Barcelona 08035, Spain
    J Natl Cancer Inst 99:628-38. 2007
    ....
  47. doi Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Rafael G Amado
    Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
    J Clin Oncol 26:1626-34. 2008
    ..Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials...
  48. ncbi Structural basis of West Nile virus neutralization by a therapeutic antibody
    Grant E Nybakken
    Department of Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Nature 437:764-9. 2005
    ..Collectively, our results suggest that a vaccine strategy targeting the dominant DIII epitope may elicit safe and effective immune responses against flaviviral diseases...
  49. pmc Rapid cloning of high-affinity human monoclonal antibodies against influenza virus
    Jens Wrammert
    Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Nature 453:667-71. 2008
    ..We used the immunoglobulin variable regions isolated from sorted single ASCs to produce over 50 human monoclonal antibodies (mAbs) that bound to the three influenza vaccine strains with high affinity...
  50. ncbi Complete replication of hepatitis C virus in cell culture
    Brett D Lindenbach
    Center for the Study of Hepatitis C, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Science 309:623-6. 2005
    ..HCVcc replication was inhibited by interferon-alpha and by several HCV-specific antiviral compounds, suggesting that this in vitro system will aid in the search for improved antivirals...
  51. ncbi Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    Kathy Miller
    Indiana University Cancer Center, Indianapolis, USA
    N Engl J Med 357:2666-76. 2007
    ....
  52. doi Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review
    Jolien Tol
    Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Clin Ther 32:437-53. 2010
    ..Currently available agents in these groups are the anti-VEGF antibody bevacizumab and the anti-EGFR antibodies cetuximab and panitumumab...
  53. doi Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV)
    Roberto Burioni
    Laboratorio di Microbiologia e Virologia, Universita Vita Salute San Raffaele, Via Olgettina 60, 20132 Milan, Italy
    Virology 399:144-52. 2010
    ..Finally, the human genes coding for the neutralizing HMabs could be used for generating full human monoclonal IgGs that can be safely administered being potentially useful in the prophylaxis and the treatment of this human infection...
  54. pmc A comprehensive toolkit of plant cell wall glycan-directed monoclonal antibodies
    Sivakumar Pattathil
    Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, USA
    Plant Physiol 153:514-25. 2010
    A collection of 130 new plant cell wall glycan-directed monoclonal antibodies (mAbs) was generated with the aim of facilitating in-depth analysis of cell wall glycans...
  55. ncbi An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus
    Elisabetta Traggiai
    Institute for Research in Biomedicine, Via Vela 6, CH 6500 Belllinzona, Switzerland
    Nat Med 10:871-5. 2004
    ..immediate protection against microbial infection, but methods to rapidly generate human neutralizing monoclonal antibodies are not yet available...
  56. pmc Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41
    M B Zwick
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 75:10892-905. 2001
    ..g., subtypes B, C, and E). The results suggest that a rather extensive region of gp41 close to the transmembrane domain is accessible to neutralizing Abs and could form a useful target for vaccine design...
  57. ncbi Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases
    Frank Winkler
    E L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Cancer Cell 6:553-63. 2004
    ..During the normalization window, but not before or after it, VEGFR2 blockade increases pericyte coverage of brain tumor vessels via upregulation of Ang1 and degrades their pathologically thick basement membrane via MMP activation...
  58. ncbi Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    James A Bonner
    Department of Medicine, University of Alabama, Birmingham, USA
    N Engl J Med 354:567-78. 2006
    ....
  59. ncbi A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
    Katrien Berns
    Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Cancer Cell 12:395-402. 2007
    ..Thus, assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to respond to trastuzumab-based therapy...
  60. ncbi Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
    M Feldmann
    Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, 1 Aspenlea Road, London W6 8LH, United Kingdom
    Annu Rev Immunol 19:163-96. 2001
    ..Infliximab (a mAB), and etanercept (a sTNF-R-Fc fusion protein) have been approved by regulatory authorities in the United States and Europe for treating RA, and they represent a significant new addition to available therapeutic options...
  61. pmc Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
    Bryan P Schneider
    Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 26:4672-8. 2008
    ..Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer...
  62. ncbi Neutralization and antibody-dependent enhancement of dengue viruses
    Scott B Halstead
    Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    Adv Virus Res 60:421-67. 2003
  63. doi Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure
    Richard Strasser
    Institute of Applied Genetics and Cell Biology, University of Natural Resources and Applied Life Sciences, Muthgasse 18, 1190 Vienna, Austria
    Plant Biotechnol J 6:392-402. 2008
    ..The generated RNAi lines were stable, viable and did not show any obvious phenotype, thus providing a robust tool for the production of therapeutically relevant glycoproteins in plants with a humanized N-glycan structure...
  64. pmc Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1
    Penny L Moore
    Torrey Pines Institute for Molecular Studies, San Diego, CA 92121, USA
    J Virol 80:2515-28. 2006
    ..We hypothesize that these nonfunctional forms of Env on particle surfaces serve to divert the antibody response, helping the virus to evade neutralization...
  65. doi PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
    Fotios Loupakis
    Department of Oncology, Azienda USL 6, Istituto Toscano Tumori, Livorno, Italy
    J Clin Oncol 27:2622-9. 2009
    ..This retrospective study investigated the role of PTEN loss, AKT phosphorylation, and KRAS mutations on the activity of cetuximab plus irinotecan in patients with metastatic colorectal cancer (mCRC)...
  66. ncbi Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
    Y Lu
    Department of Oncology, Jewish General Hospital, and McGill University, Montreal, PQ, Canada
    J Natl Cancer Inst 93:1852-7. 2001
    ..Thus, strategies that target IGF-IR signaling may prevent or delay development of resistance to trastuzumab...
  67. ncbi Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
    Kevan C Herold
    Naomi Berrie Diabetes Center and the Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York 10032, USA
    N Engl J Med 346:1692-8. 2002
    ..Preclinical studies suggested that a monoclonal antibody against CD3 could reverse hyperglycemia at presentation and induce tolerance to recurrent disease...
  68. ncbi PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    Yoichi Nagata
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 6:117-27. 2004
    ..Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance...
  69. ncbi Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Biochem Biophys Res Commun 333:328-35. 2005
    ..Substantial evidence also implicates VEGF as a mediator of pathological angiogenesis. Anti-VEGF monoclonal antibodies and other VEGF inhibitors block the growth of several tumor cell lines in nude mice...
  70. ncbi Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
    Shiqing Li
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Cell 7:301-11. 2005
    ..We suggest that both these effects contribute to potent inhibition of EGFR activation...
  71. ncbi Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet 370:2103-11. 2007
    ..Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa was warranted...
  72. doi Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins
    Shee Mei Lok
    Department of Biological Sciences, Purdue University, 915 West State Street, West Lafayette, Indiana 47907 2054, USA
    Nat Struct Mol Biol 15:312-7. 2008
    ..The changes in the structure of the viral surface are presumably responsible for inhibiting attachment to cells...
  73. doi EGFR antagonists in cancer treatment
    Fortunato Ciardiello
    Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, Naples, Italy
    N Engl J Med 358:1160-74. 2008
  74. ncbi KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Astrid Lievre
    Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale UMR 775, Paris, France
    Cancer Res 66:3992-5. 2006
    ..The EGFR amplification, which is not as frequent as initially reported, is also associated with response to this treatment...
  75. pmc Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells
    W D Crill
    Arbovirus Disease Branch, Division of Vector Borne Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, U S Department of Health and Human Services, Fort Collins, Colorado 80522, USA
    J Virol 75:7769-73. 2001
    ..detail, we analyzed the ability of a well-defined set of anti-dengue (DEN) virus E-glycoprotein-specific monoclonal antibodies (MAbs) to block virus adsorption to Vero cells...
  76. ncbi Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor
    Shyhmin Huang
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792 0600, USA
    Cancer Res 64:5355-62. 2004
    ..This approach suggests potential new strategies to maximize effective target inhibition, which may improve the therapeutic ratio for anti-EGFR-targeted therapies in developing clinical trials...
  77. pmc Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2
    Soila Sukupolvi-Petty
    Department of Medicine, Washington University School of Medicine, 660 South Euclid Ave, Box 8051, St Louis, MO 63110, USA
    J Virol 84:9227-39. 2010
    ..Although prior studies have characterized the neutralizing activity of monoclonal antibodies (MAbs) against DENV type 2 (DENV-2), none have compared simultaneously the inhibitory activity against a ..
  78. pmc Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins
    Taia T Wang
    Department of Microbiology Mount Sinai School of Medicine New York, New York, United States of America
    PLoS Pathog 6:e1000796. 2010
    ..Three monoclonal antibodies have been identified that are broadly-neutralizing against H3 influenza viruses spanning 40 years...
  79. pmc Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein
    Ania M Owsianka
    Institute of Virology, University of Glasgow, Church Street, Glasgow G11 5JR, UK
    J Gen Virol 89:653-9. 2008
    ..We previously isolated human monoclonal antibodies to conformational epitopes on the HCV E2 glycoprotein...
  80. pmc Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta
    K Nakamura
    Mucosal Immunity Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 194:629-44. 2001
    ..This, plus the fact that we could find no evidence that a soluble factor mediates suppression, strongly suggests that CD4(+)CD25(+) T cells exert immunosuppression by a cell-cell interaction involving cell surface TGF-beta1...
  81. ncbi Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    David Cunningham
    Royal Marsden Hospital, London, United Kingdom
    N Engl J Med 351:337-45. 2004
    ..We compared the efficacy of cetuximab in combination with irinotecan with that of cetuximab alone in metastatic colorectal cancer that was refractory to treatment with irinotecan...
  82. ncbi Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation
    Yoshikatsu Kaneko
    Laboratory of Molecular Genetics and Immunology, Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Science 313:670-3. 2006
    ..This differential sialylation may provide a switch from innate anti-inflammatory activity in the steady state to generating adaptive pro-inflammatory effects upon antigenic challenge...
  83. ncbi Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Stanley B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Arthritis Rheum 54:2793-806. 2006
    ....
  84. ncbi Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis
    B T Wipke
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Immunol 167:1601-8. 2001
    ..These studies have identified a critical role for neutrophils in initiating and maintaining inflammatory processes in the joint...
  85. pmc High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, 27710, United States
    J Virol Methods 158:171-9. 2009
    ..These Ig gene expression cassettes constitute a highly efficient strategy for rapid expression of Ig genes for high-throughput screening and analysis without cloning...
  86. pmc Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions
    S Moses Dennison
    Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Virol 83:10211-23. 2009
    ..in liposomes and to determine how the orientation of the MPER with lipids affects the binding kinetics of monoclonal antibodies (MAbs) 2F5 and 4E10...
  87. doi Rheumatoid arthritis
    Lars Klareskog
    Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
    Lancet 373:659-72. 2009
    ..Understanding the cause and pathogenesis of different rheumatoid arthritis subsets will lead not only to individualised treatments during early phases of the illness but also, possibly, to disease prevention...
  88. doi Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wohrendamm 80, 22927 Grosshansdorf, Germany
    J Clin Oncol 27:1227-34. 2009
    ..This randomized phase III trial investigated the efficacy and safety of cisplatin/gemcitabine (CG) plus bevacizumab in this setting...
  89. ncbi Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
    R A Clynes
    Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Ave, New York, New York 10021, USA
    Nat Med 6:443-6. 2000
    ..Mouse monoclonal antibodies, as well as the humanized, clinically effective therapeutic agents trastuzumab (Herceptin(R)) and ..
  90. doi Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H 917, New York, NY 10021, USA
    J Clin Oncol 26:2013-9. 2008
    ....
  91. pmc Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions
    S L Zebedee
    Department of Biochemistry, Molecular Biology, Northwestern University, Evanston, Illinois 60208
    J Virol 62:2762-72. 1988
    ....
  92. pmc A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    James C Yang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 349:427-34. 2003
    ..We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma...
  93. ncbi Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network
    Christoph A Ritter
    Institute of Pharmacology, University of Greifswald, Greifswald, Germany
    Clin Cancer Res 13:4909-19. 2007
    ..We have investigated mechanisms of acquired resistance to the HER2 antibody trastuzumab in BT-474 human breast cancer cells...
  94. ncbi Targeting of CD44 eradicates human acute myeloid leukemic stem cells
    Liqing Jin
    Division of Cell and Molecular Biology, University Health Network Suite 8 355, Toronto Medical Discovery Tower, 101 College Street, Toronto, M5G 1L7, Canada
    Nat Med 12:1167-74. 2006
    ..The finding that AML LSCs require interaction with a niche to maintain their stem cell properties provides a therapeutic strategy to eliminate quiescent AML LSCs and may be applicable to other types of cancer stem cells...
  95. pmc Interleukin 6 is required for the development of collagen-induced arthritis
    T Alonzi
    Istituto Ricerche di Biologia Molecolare P Angeletti, 00040 Pomezia, Rome, Italy
    J Exp Med 187:461-8. 1998
    ..These results are discussed in the light of the present knowledge of cytokine networks in chronic inflammatory disorders and suggest that IL-6 receptor antagonists might be beneficial for the treatment of RA...
  96. pmc Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
    D L Wheeler
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Oncogene 27:3944-56. 2008
    ..Five EGFR inhibitors, two monoclonal antibodies and three TKIs, have recently gained FDA approval in oncology (cetuximab, panitumumab, erlotinib, ..
  97. pmc Monoclonal antibodies to heat shock protein 60 alter the pathogenesis of Histoplasma capsulatum
    Allan J Guimaraes
    Department of Medicine Division of Infectious Diseases and Microbiology and Immunology, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York 10461, USA
    Infect Immun 77:1357-67. 2009
    ..We generated immunoglobulin G (IgG) isotype monoclonal antibodies (MAbs) to H. capsulatum Hsp60...
  98. ncbi Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
    Gerrit Jan Wolbink
    Department of Immunopathology, CLB Sanquin Amsterdam and Jan van Breeman Institute, Amsterdam, The Netherlands
    Arthritis Rheum 54:711-5. 2006
    ..This study evaluated the clinical significance of these antibodies in patients with rheumatoid arthritis (RA)...
  99. ncbi Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
    A M Shapiro
    Surgical Medical Research Institute and the Department of Surgery, University of Alberta, Edmonton, Canada
    N Engl J Med 343:230-8. 2000
    ..Registry data on patients with type 1 diabetes mellitus who undergo pancreatic islet transplantation indicate that only 8 percent are free of the need for insulin therapy at one year...
  100. doi Treatment with monoclonal antibodies against Clostridium difficile toxins
    Israel Lowy
    Medarex, Princeton, NJ, USA
    N Engl J Med 362:197-205. 2010
    ..New therapies are needed to manage the increasing incidence, severity, and high rate of recurrence of Clostridium difficile infection...
  101. pmc In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination
    Laura C Bonifaz
    Laboratory of Cellular Physiology and Immunology, Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, NY 10021, USA
    J Exp Med 199:815-24. 2004
    ....

Research Grants71

  1. Anti-Autolysin Passive Immunity for MRSA Osteomyelitis
    JOHN LINFORTH DAISS; Fiscal Year: 2010
    ..Currently, the company has 13 monoclonal antibodies against glucosaminidase that it needs to screen to derive a primary, secondary and tertiary candidate for ..
  2. CFI Pathogen Inactivation Technology
    Trevor P Castor; Fiscal Year: 2010
    ..and human plasma proteins, the developed technology will also be applicable to recombinant therapeutics, monoclonal antibodies, transgenics and vaccines...
  3. Cardiotrophin-Like Cytokine 1, a Candidate Molecule for the FSGS Factor
    Virginia J Savin; Fiscal Year: 2010
    ..the vigorous activity of CLC-1 in the Palb assay and finally, e.) the striking ability of anti-CLC-1 monoclonal antibodies to block the permeability effect of FSGS plasma...
  4. SUPPORT CONTRACT FOR THE NTP INTERAGENCY CENTER/VALIDATION OF ALT METHODS
    David Allen; Fiscal Year: 2009
    ..include vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, monoclonal antibodies, and recombinant therapeutic proteins that are used to treat or protect humans or animals...
  5. Notch and Regulators of Notch Signaling Impact Both Glucose and Lipid Metabolism
    UTPAL BHAGIRATH PAJVANI; Fiscal Year: 2013
    ..study the effects of inhibition of Notch signaling with pharmacologic tools (small molecule inhibitors or monoclonal antibodies) or other genetic mouse models of Notch hypofunction. Additionally, Dr...
  6. Expression of sFlt1 and its function in the glomerular endothelium
    Christie P Thomas; Fiscal Year: 2013
    ..the proteinuria and hypertension frequently seen in patients undergoing chemotherapy with anti-VEGF monoclonal antibodies or with tyrosine kinase inhibitors and provides a model to study the role of VEGF and its receptors in ..
  7. VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGED
    Rafi Ahmed; Fiscal Year: 2013
    ..Immune Senescence (Goronzy), and a Technology Development Project on Human Monoclonal Antibodies (Wilson/Lanzavecchia)...
  8. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2013
    ..Radiolabeled anti-CD45 monoclonal antibodies (Ab) have been shown to improve outcomes for AML and MDS in the setting of HCT, but toxicity remains high ..
  9. Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo
    Lynda G Tussey; Fiscal Year: 2013
    ..Based on recent findings of neutralizing epitopes of human polyclonal and monoclonal antibodies, we have generated backup subunit flagellin-E vaccines that include major neutralizing epitopes in the ..
  10. A XENOPUS LAEVIS RESEARCH RESOURCE FOR IMMUNOBIOLOGY
    Jacques Robert; Fiscal Year: 2013
    ..tools including MHC-defined isogenetic clones and inbred strains of animals, transgenic lines, cell lines, monoclonal antibodies, and cDNA probes that need to be preserved, enriched and made available to the scientific community...
  11. A Novel Model of, and Pre-clinical Therapy for, Scleroderma Lung Disease
    Sergei P Atamas; Fiscal Year: 2012
    ..Specifically, the experiments will assess the efficacy of hIL-442-blocking monoclonal antibodies, and blockade of human IL-442 production through RNA interference...
  12. Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders
    Bruce S Bochner; Fiscal Year: 2013
    ..The goal of the present application is to employ monoclonal antibodies (mAbs) and glycan ligands for Siglec-8 in highly translational, preclinical in vitro and murine studies (..
  13. Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders
    Bruce S Bochner; Fiscal Year: 2012
    ..The goal of the present application is to employ monoclonal antibodies (mAbs) and glycan ligands for Siglec-8 in highly translational, preclinical in vitro and murine studies (..
  14. Prevention and therapy of Staphylococcus aureus infections
    Olaf Schneewind; Fiscal Year: 2010
    ..Enabled by the availability of an exciting new technology - high-throughput isolation of monoclonal antibodies from human plasmoblasts - we propose here the systematic analyses of B cell responses for neutralizing ..
  15. Noncoding RNA targets of the spinal muscular atrophy protein
    Livio Pellizzoni; Fiscal Year: 2010
    ..First, ncRNAs will be isolated from whole cell extracts by immunoprecipitation with specific monoclonal antibodies. Then, cDNA libraries will be generated from each immunoprecipitate and comprehensive identification of ..
  16. Th2 Cytokines and Signaling in Pediatric Inflammatory Bowel Disease
    Michael J Rosen; Fiscal Year: 2013
    ..In fact, monoclonal antibodies against IL-13, a proposed pathogenic Th2 cytokine, are in phase 2 trials for UC...
  17. Discovery of Critical Host Genes Enabling Resistance to HIV-1 Infection as Therap
    Leyla S Diaz; Fiscal Year: 2012
    ..Robo1 antibodies exhibited anti-HIV-1 activity in human PBMC assays. Robo1 thus can be targeted by monoclonal antibodies to block HIV life cycle and/or to eliminate infected cells via normal host defense mechanisms such as ..
  18. Impact of genetic variation on response to GO therapy in COG-AML clinical trials
    ROLAND BRUNO WALTER; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): An emerging approach in acute myeloid leukemia (AML) uses monoclonal antibodies as a means to deliver targeted therapy...
  19. IMMUNOLOGY OF UNIQUE TUMOR SPECIFIC ANTIGENS
    Hans Schreiber; Fiscal Year: 2013
    ..Three such monoclonal antibodies, 237, 5E5 and 3H4, have been cloned and sequenced to generate (i) chimeric antibody receptors (CARs) for ..
  20. Mechanism of PsrP mediated adhesion
    Carlos J Orihuela; Fiscal Year: 2013
    ..We will determine the segment of BR that is responsible for PsrP-mediated binding. We will develop monoclonal antibodies (mAbs) against BR and determine if they inhibit bacterial adhesion, affect biofilm formation, and protect ..
  21. PA-50/PA-41 antitoxin antibody therapy for C. difficile infection
    William C Olson; Fiscal Year: 2012
    ..One experimental treatment strategy is to neutralize the toxins with monoclonal antibodies (mAbs)...
  22. Tumor drug delivery systems based on polymalic acid
    Julia Y Ljubimova; Fiscal Year: 2010
    ..Aim 2b. Optimization of the number and relative abundance of cell targeting monoclonal antibodies on PMLA carrier for facilitating BTB penetration and increasing tumor targeting specificity...
  23. Target discovery and immunoassay for diagnosis of invasive aspergillosis
    Thomas R Kozel; Fiscal Year: 2013
    ..The second R33 phase will be immunoassay development and evaluation. Polyclonal and monoclonal antibodies will be produced to target proteins;immunoassays will be constructed that target the most promising ..
  24. Tumor -Targeting Chemotherapeutic Agents
    Iwao Ojima; Fiscal Year: 2013
    ..We have successfully targeted tumor xenografts in animal models by employing monoclonal antibodies and polyunsaturated fatty acids...
  25. Antibody Mediated Autoimmunity in Neuromyelitis Optica
    HANS CHRISTIAN VON BUEDINGEN; Fiscal Year: 2013
    ..recombinant monoclonal antibodies (rAbs) generated from CSF plasma cells, and by b...
  26. Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
    Darell D Bigner; Fiscal Year: 2013
    ..Targeted immunotherapy with monoclonal antibodies (MAbs) or their fragments armed with Astatine 211 or Pseudomonas exotoxin for the treatment of NM or GBM ..
  27. ESTABLISHMENT/MAINTENANCE OF BIOMEDICAL RESEARCH COLONY
    Thomas J Rowell; Fiscal Year: 2011
    ..pharmacokinetics, bioavailablity, safety, and efficacy of novel drug compounds, proteins and monoclonal antibodies. Specific aims of the application include the following: * To maintain capabilities to successfully breed (..
  28. Key determinants of dengue virus neutralization by naturally occurring human mAbs
    Scott A Smith; Fiscal Year: 2013
    ..forms the basis of the science in the current application, is focused on generation and study of human monoclonal antibodies to dengue viruses...
  29. Multilevel Targeted Therapeutics Using Surface Functionalized Nanoparticles encap
    JILL STEINBACH; Fiscal Year: 2012
    ..In parallel, research at the protein level has uncovered monoclonal antibodies (mAbs) that can intercept virus attachment to host receptors such as nectin-1...
  30. Chimpanzee Biomedical Research Program Limited Competition (U42)
    M Babette Fontenot; Fiscal Year: 2013
    ..pharmacokinetics, bioavailability, safety, and efficacy of novel drug compounds, proteins and monoclonal antibodies. Specific aims of the application include the following: 1) To maintain CBRP chimpanzees in a setting ..
  31. Development of Cytokine-Inhibiting Gels for Treating Chronic Wounds
    Newell R Washburn; Fiscal Year: 2010
    ..The gels are composed of monoclonal antibodies that neutralize pro-inflammatory cytokines, such as tumor necrosis factor- 1, which have been covalently ..
  32. BETR Therapy for Herpesvirus-Associated Tumors
    Martin G Pomper; Fiscal Year: 2013
    ..g., those expressing the B cell surface molecule CD20. Monoclonal antibodies and radioimmunoconjugates such as [131I]Tositumomab (Bexxar") and [90Y]ibritumomab iuxetan (Zevalin") have ..
  33. Chromatin Immunoprecipitation (ChIP) Assay Development for FFPE human brain secti
    Mary Anne Jelinek; Fiscal Year: 2011
    ..tissue model system, and in conjunction with the isolation of a panel of highly characterized and specific monoclonal antibodies to histone modifications associated with either transcriptionally active or repressed loci, will be used ..
  34. MECHANISMS OF ALLOGENEIC STEM CELL EDUCATION IN SCID
    Rebecca H Buckley; Fiscal Year: 2010
    ..the phenotypes and functions of DN and y6 T cells after allogeneic stem cell therapy in SCID using monoclonal antibodies and multi-color flow cells cells. develop We but that circulating will as also examine for r...
  35. Development of Therapeutic Pan-Filovirus Macaque Monoclonal Antibodies
    Sven G Enterlein; Fiscal Year: 2013
    ..Upon successful completion of this Phase I SBIR we envision a Phase II focused on demonstration of protective efficacy in NHP models and standard pre-clinical development activities in preparation for regulatory filing. ..
  36. A novel vaccine to prevent HCV infection and hence liver cancer
    Ellen S Vitetta; Fiscal Year: 2010
    ..In this proposal we plan to use a panel of neutralizing monoclonal antibodies (MAbs) against HCV for screening...
  37. Mechanisms used by skin dendritic cells to induce regulatory T cells
    Juliana Idoyaga; Fiscal Year: 2013
    ..Using a novel approach that consists of directing antigens to different subsets of DCs in vivo using monoclonal antibodies against surfac receptors, we have found strong evidence that not all DCs have the ability to induce ..
  38. Therapeutic Opportunities of Targeting Tissue Factor Signaling in Obesity
    Fahumiya Samad; Fiscal Year: 2013
    ..Evaluating the effect of monoclonal antibodies that selectively inhibit direct TF-VIIa-PAR2 signaling in transgenic mice expressing human TF will ..
  39. ASTATINE AND IODINE RADIOLABELED MONOCLONAL ANTIBODIES
    Michael Rod Zalutsky; Fiscal Year: 2013
    ..conduct all the toxicity, efficacy, dosimetry, and other FDA-required studies for Investigational New Drug permits, to all performance of clinical trials in malignant glioma patients under our Brain Tumor Center grant (NS20023 ..
  40. Humanization of a mouse anti-OX40 monoclonal antibody to treat cancer
    Andrew D Weinberg; Fiscal Year: 2012
    ..Recent clinical studies using monoclonal antibodies that enhance T cell function in cancer patients have shown significant anti-tumor efficacy in refractory ..
  41. Infant immunoprophylaxis against a primate lentivirus
    RUTH MARGRIT RUPRECHT; Fiscal Year: 2012
    ..funding period, we have provided proof-of-concept that combinations of human broadly reactive neutralizing monoclonal antibodies (brnmAbs) can completely protect neonatal rhesus monkeys from oral simian-human immunodeficiency virus (..
  42. Bioactive lipids in food and pharmaceutical products
    Eric J Haas-Stapleton; Fiscal Year: 2013
    ..We investigated PGE2 levels in alcoholic beverages using monoclonal antibodies having high specificity for PGE2 and detected PGE2 in beer and sake...
  43. Microfibril Fragments: Biomarkers of Aortic Disease
    Lynn Y Sakai; Fiscal Year: 2010
    ..In contrast, our approach relies upon the exquisite specificities of monoclonal antibodies to detect fragments that are so far uncharacterized...
  44. Influenza Immunity: Protective Mechanisms Against Pandemic Respiratory Virus
    MARK MORRIS DAVIS; Fiscal Year: 2013
    ..with TIV or LAIV in the different age groups and compare the specificity and affinity of these monoclonal antibodies against both homotypic and heterovariant influenza viruses. A2...
  45. Diagnostic tools to link Bacteroides fragilis toxin isotypes and human disease
    Saraspadee Mootien; Fiscal Year: 2012
    ..The second is an ELISA-based assay that will use monoclonal antibodies directed against the known isotypes of BFT, to identify directly from stool samples whether ongoing ..
  46. Catalytic Antibody-Based Vaccine For Weight Loss
    AMANDA LEE GARNER; Fiscal Year: 2010
    ..2) We will utilize the synthesized haptens for the immunization of mice to generate monoclonal antibodies. (3) We will characterize each catalytic antibody for its kinetic efficiency...
  47. Susceptibility and Protective Immunity to Noroviruses
    Ralph S Baric; Fiscal Year: 2013
    ..4 challenge model in swine and characterizes human monoclonal antibodies (mAb) to GI and GII strains, providing key reagents for advancing the field...
  48. ANTIGEN SPECIFIC T CELL TOLERANCE BY ANTI CD3 ANTIBODIES
    Claudio Anasetti; Fiscal Year: 2012
    ..TCR engagement can induce either T cell proliferation and differentiation or AICD. Monoclonal antibodies (mAb) to CD3, a monomorphic chain associated to the TCR complex, mimic antigen and induce TCR signaling ..
  49. Uncovering the Regulatory Role of gH/gL in HSV Fusion
    Roselyn J Eisenberg; Fiscal Year: 2013
    ..In Aim 1, we will dissect the nature of the complex formed by gH/gL with gB with mutants and monoclonal antibodies. Techniques such as biosensor analysis, calorimetry, cryo-EM tomography and X-ray crystallography will be ..
  50. Monolithic Media and Technology for Bioprocessing
    ALEX G BONNER; Fiscal Year: 2011
    ..Purification technology for large biomolecules such as monoclonal antibodies is an important component of biological research and for the production of therapeutic proteins that are ..
  51. Developing A Novel Therapy for Diabetic Retinopathy
    Danyang Chen; Fiscal Year: 2013
    ..Through generating and screening a series of mouse anti-human LRP6 monoclonal antibodies (mAbs), 2F1mab has been identified as a specific anti-LRP6 mAb and a potent Wnt inhibitor...
  52. Protective Human Monoclonal Antibodies to HIV-1
    SUSAN B ZOLLA-PAZNER; Fiscal Year: 2012
    ..These antibodies could also be used to develop products to treat HIV infection when used in conjunction with anti-retroviral drugs. ..
  53. Rapid Point-of-Care Test Kit for the Detection of Bacteriuria Calibrated for Imme
    MARK GEISBERG; Fiscal Year: 2010
    ..In the test design, anti-bacteria monoclonal antibodies (MAbs) will be used to directly bind to bacterial cells in a urine sample, producing a visual result ..
  54. Novel Tetravalent Vaccines for Dengue Virus
    ROBERT GERALD WHALEN; Fiscal Year: 2013
    ..We will prepare monoclonal antibodies both to study the mechanism of tetravalent immunogenicity and to provide reagents for manufacturing ..
  55. Direct IL-4 and IL-13 effects on pulmonary smooth muscle in allergic airway disea
    FRED DOUGLASS FINKELMAN; Fiscal Year: 2010
    ..Proposed experiments will use transgenic mice, recombinant cytokines, monoclonal antibodies, cell transfer systems, assays of in vivo cytokine production, flow cytometry and 3 different techniques ..
  56. Nanopore Biosensor for Kinetics of Reparative Antibodies on Plasma Membranes
    Sang Hyun Oh; Fiscal Year: 2013
    ..will validate these membrane biosensing concepts by characterizing the binding of therapeutic human monoclonal antibodies to candidate antigens. These human IgMs promote remyelination of demyelinated lesions and preserve axons...
  57. GUCY2C targeted adoptive T cell therapy to treat metastatic colorectal cancer
    Michael S Magee; Fiscal Year: 2013
    ..cell signaling domains to antigen-recognizing single-chain fragment variable regions from GUCY2C-specific monoclonal antibodies. These receptors offer a substantial advantage compared to endogenous antigen- specific T cells because ..
  58. Optimization of Protein Therapeutics Formulations
    Lawrence J Delucas; Fiscal Year: 2012
    ..e. vaccines, monoclonal antibodies and other therapeutic proteins)...
  59. Evaluation of In Vitro Companion Diagnostic Monoclonal Antibodies for Use in a St
    Christopher Horvath; Fiscal Year: 2013
    ..Combined use of anti-DEspR companion diagnostic and therapeutic mAbs has the potential to alter oncology clinical practice, particularly in BCa/TNBC, as an addition to or advantage over existing treatments. ..
  60. A Proof of Concept Study Examining The Safety and Efficacy of Innate Immune Syste
    Ted T Ashburn; Fiscal Year: 2013
    ..removing toxic species of A[unreadable] or preventing their build up, either through the administration of monoclonal antibodies against one or more forms of A[unreadable] or antagonists of enzymes involved in its formation have, to ..
  61. Improving Antibodies to Virion Based HIV Vaccines
    Kathie Grovit-Ferbas; Fiscal Year: 2013
    ..During our initial funding period, we have isolated a panel of monoclonal antibodies (mAbs) immunized with Env modified heat treated virions...
  62. Functional and Structural Studies of CD74 Activation
    Elias Lolis; Fiscal Year: 2010
    ..Some experiments show that it is necessary for the rapid uptake of HLA-DR-specific monoclonal antibodies into early endosomes and for peptide loading on the cell surface, but cell-surface CD74 does not always ..
  63. CENTER FOR CANCER BIOLOGY RESEARCH
    W Keith Miskimins; Fiscal Year: 2011
    ..Project 3 (Satoshi Nagata, PhD) will develop a panel of monoclonal antibodies to surface antigens that are highly expressed in B cell malignancies...
  64. Selection and Characterization of PSMA Ligands from Phage-Displayed Libraries
    Gary Fujii; Fiscal Year: 2006
    ..RRPs offer many advantages over monoclonal antibodies, including rapid turnaround and economical expression...
  65. PROTEOGLYCAN SYNTHESIS DURING DEVELOPMENT AND AGING
    Arnold Caplan; Fiscal Year: 1999
    ..The availability of specific monoclonal antibodies to unique carbohydrate domains provides the tools to analyze these chains of aggrecan with a high ..
  66. COLLAGENS OF HYALINE CARTILAGE
    Richard Mayne; Fiscal Year: 2002
    ..Extensive use will be made to high affinity monoclonal antibodies (mAbs) specific for each collagen type for which the location of different epitopes along the collagen ..
  67. Glycosylation of full-length antibodies in Escherichia coli
    ADAM FISHER; Fiscal Year: 2009
    ..Since monoclonal antibodies require glycosylation to provide full therapeutic benefit, mammalian cell culture is the expression ..
  68. High Mannose Type Carbohydrate-based HIV/AIDS Vaccine
    Yu Geng; Fiscal Year: 2009
    ..Second, one of the few broadly neutralizing HIV monoclonal antibodies, 2G12, recognizes a conformational epitope of high mannose type glycans on gp120...
  69. Structure Based Design of Humanized Monoclonal Antibodies that Recognize Bioactiv
    JONATHAN WOJCIAK; Fiscal Year: 2009
    ..than directing antibodies against protein targets, Lpath has been successful in generating therapeutic monoclonal antibodies (mAbs) against a novel class of therapeutic targets, bioactive lipids...
  70. CTL2 ELISA: A Diagnostic Test for Autoimmune Hearing Loss
    Vijay Kumar; Fiscal Year: 2007
    ..This prominent and abundant protein is expressed on the surface of inner ear supporting cells (IESC). Monoclonal antibodies against CTL2 have been shown to induce hearing loss in an experimental guinea pig model...
  71. HEAD AND NECK CARCINOMA CELL KINETICS
    Marc Coltrera; Fiscal Year: 1993
    ..of the project are to: a) study tumor cell kinetics in head and neck carcinomas using newly-developed monoclonal antibodies which identify proliferating cells in tissue sections and; b)develop a new classification system of head ..